By rray, 21 December, 2023 Exclude Patient Type Detail Header No Detail Type Text Detail Text In adults w T2DM and established or high risk of ASCVD HF and or CKD tx plan should include agent s that reduce s CV and kidney dz risk e g SGLT2 and or GLP 1 RA for glycemic mgmt and comprehensive CV risk reduction independent of A1C and in consideration In pts who have HF w either reduced or preserved EF an SGLT2 inhibitor is recommended for glycemic mgmt and prevention of HF hospitalizations A In pts who have CKD w confirmed eGFR of 20 60 and or albuminuria use an SGLT2 inhibitor to minimize progression of CKD and reduce CKD events and HF hospitalizations Note Glycemic benefits of SGLT2 inhibitors are reduced at eGFR In pts w advanced CKD eGFR Patient Type Detail Header (Long) Adults w/ CV or renal dz